John McHutchison
Director/Board Member presso ASSEMBLY BIOSCIENCES, INC.
Patrimonio netto: 282 239 $ in data 31/05/2023
Profilo
John G.
McHutchison is the founder of Actio Biosciences, Inc. (founded in 2021).
He is currently the President & Chief Executive Officer at Velia, Inc. (since 2023), a Director at Assembly Biosciences, Inc. (since 2019), a Director at Evox Therapeutics Ltd.
(since 2021), a Director at Tune Therapeutics, Inc. (since 2023), and a Member of The Royal Australasian College of Physicians.
Previously, he served as a Director at Oxford BioTherapeutics Ltd.
(2017-2023), Associate Director at Duke Clinical Research Institute, Medical Director-Liver Transplantation at Scripps Clinic & Research Foundation, and Independent Director at Metacrine, Inc. (2020-2023).
He was also the Chief Scientific Officer and Head of R&D at Gilead Sciences, Inc. (2018-2019).
Additionally, he held positions as an Assistant Professor at the University of Southern California and a Professor at Duke University Medical Center.
Dr. McHutchison completed his undergraduate and doctorate degrees at the University of Melbourne.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/04/2024 | 21 221 ( 0.39% ) | 282 239 $ | 31/03/2024 | |
METACRINE INC
-.--% | 03/02/2023 | 0 ( -.--% ) | - $ | 31/05/2023 |
Posizioni attive di John McHutchison
| Società | Posizione | Inizio |
|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Director/Board Member | 06/08/2019 |
| The Royal Australasian College of Physicians | Corporate Officer/Principal | - |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | 18/01/2021 |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Director/Board Member | 17/01/2023 |
Velia, Inc.
 Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Chief Executive Officer | 19/07/2023 |
Precedenti posizioni note di John McHutchison
| Società | Posizione | Fine |
|---|---|---|
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | 24/04/2023 |
| METACRINE, INC. | Director/Board Member | 23/03/2023 |
| GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02/08/2019 |
Actio Biosciences, Inc.
 Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Founder | - |
| ░░░░░░░ ░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di John McHutchison
| University of Melbourne | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| METACRINE, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Duke Clinical Research Institute
 Duke Clinical Research Institute Pharmaceuticals: OtherHealth Technology Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC. | Health Technology |
| Scripps Clinic & Research Foundation | |
| The Royal Australasian College of Physicians | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Health Technology |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Technology Services |
Actio Biosciences, Inc.
Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Health Technology |
- Borsa valori
- Insiders
- John McHutchison
